Volume 60, Issue 4 pp. 682-687
Research Article

New health conditions identified at a regional childhood cancer survivor clinic visit

Mary-Jane Staba Hogan MD, MPH

Corresponding Author

Mary-Jane Staba Hogan MD, MPH

Department of Pediatrics, Section of Hematology–Oncology, Yale School of Medicine, New Haven, Connecticut

Department of Pediatrics, Section of Hematology–Oncology, Yale School of Medicine, 333 Cedar St., LMP 2073, New Haven, CT 06520.===Search for more papers by this author
Xiaomei Ma PhD

Xiaomei Ma PhD

Division of Chronic Disease Epidemiology, Yale School of Public Health, New Haven, Connecticut

Search for more papers by this author
Nina S. Kadan-Lottick MD, MSPH

Nina S. Kadan-Lottick MD, MSPH

Department of Pediatrics, Section of Hematology–Oncology, Yale School of Medicine, New Haven, Connecticut

Search for more papers by this author
First published: 28 September 2012
Citations: 17

Conflict of interest: The authors have indicated they have no conflict of interests or financial relationships relevant to this article to disclose. Dr. Kadan-Lottick was a St. Baldrick's Foundation Scholar and the HEROS clinic and database has also been funded in part by the American Cancer Society Scholar Grant 119700-RSGHP-10-107-01-CPHPS. These financial sources were not involved in the study design; collection, analysis, or interpretation of data; or in preparation or submission of the manuscript for publication.

Abstract

Background

Specialty childhood cancer survivorship clinics have been established to screen for potential treatment-related effects. Given the limited empirical data regarding the merit of survivorship clinics, we assessed the frequencies of newly identified, therapy-related effects in survivors who attended Health, Education, Research, Outcomes for Survivors (HEROS) clinic at Yale during 2003–2009.

Procedure

A total of 213 survivors in remission, who were diagnosed with cancer at an age ≤21 years and were ≥3 years after cancer diagnosis, underwent screening based on cancer treatment exposures according to the children's oncology group long-term follow-up guidelines. The frequencies and associated factors of newly identified health conditions were determined. Odds ratios (OR) and their 95% confidence intervals were estimated using multivariate regression models with stepwise selection.

Results

Prior to the HEROS clinic visit, 49% of patients had at least one previously known late complication of therapy. After the visit, a total of 98 new health conditions were identified in 73 patients (34%). Newly identified complications in screened patients included pulmonary dysfunction (23%), endocrinopathy (19%), osteoporosis (17%), dyslipidemia (8%), neurologic impairment (4%), cardiovascular deficit (3%) and subsequent cancer (3%). Age at cancer diagnosis (OR = 1.06 [1.00–1.11]), chest irradiation (OR = 2.92 [1.58–5.40]), and history of ≥1 other treatment-related complication(s) (OR = 2.20 [1.18–4.07]) were associated with a higher likelihood of having new conditions identified.

Conclusion

Risk-based screening at a specialty childhood cancer survivor clinic detected a substantial number of previously unrecognized, treatment-related health complications in a group of survivors already receiving regular medical care elsewhere. Pediatr Blood Cancer 2013; 60: 682–687. © 2012 Wiley Periodicals, Inc.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.